Satellos Bioscience Inc.
MSLE · Pharmaceutical Preparations · EDGAR filings ↗
Grade
D45Clinical-stage micro-cap with deeply negative returns and a dangerously short cash runway.
Strengths
- High current/quick ratio (7.8x, ~74th pct) gives near-term solvency cushion
- Net loss narrowed modestly (net income growth ~63rd pct)
Risks
- Cash runway only ~1.7 quarters (13th pct) — acute funding/dilution risk
- ROE -90% and ROA -78% (~29th/31st pct), no product revenue
- FCF -$23.6M with binary clinical/funding dependence
Notable findings
- Cash burnNegative free cash flow (-23.6M)
- Notable holderHeld by 1 notable fund(s): CITADEL ADVISORS LLC (as of 2026-03-31)
- Trial readout soonUpcoming trial readout ~2026-08-30 — PHASE2 · Duchenne Muscular Dystrophy (DMD)
Key metrics
Return on equity
-89.5%
Return on assets
-78.0%
Current ratio
7.8×
Free cash flow
-$24M
Tangible book value
$28M
Cash & investments
$10M
Cash runway
2q
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07287189 ↗ | Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients Duchenne Muscular Dystrophy, Duchenne | PHASE2 | Recruiting | 2027-03-31 |
| NCT06867107 ↗ | An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101 Duchenne Muscular Dystrophy (DMD) | PHASE2 | Enrolling By Invitation | 2026-08-30 |
| NCT06565208 ↗ | First in Human SAD/MAD Safety and PK Study With Adult DMD Safety and PK Cohort Duchenne Muscular Dystrophy | EARLY_PHASE1 | Completed | 2025-04-28 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 40-F | 2026-03-27 | 2025-12-31 | 0001104659-26-035729 ↗ |